In this podcast, I (@aging_scientist) spoke with Dr. Rich Miller about the ins and outs of mouse aging.

Following our successful fundraise of $4.1 million (check out the Forbes article), a new wave of projects are in the pipeline to be funded. First up in 2023 is Brain Tissue Replacement Therapy with Jean Hebert

The Longevity field is starting the year strongly with new updated Hallmarks of aging, exactly 10 years after the original paper was published. So time to update your introduction slides with the figure we will see in every presentation for the next

2023 kicks off with strong support for longevity research and a huge step for decentralized science(DeSci)

As the end of the year is fast approaching we wanted to look back and appreciate all the effort and hard work of the researchers in the VitaDAO community - from students, postdocs and fellows to principal investigators

Therapies that act synergistically are needed to significantly promote longevity

A multitude of discoveries and inventions throughout history have been made by people who were initially trained in one domain, but were able to make a significant contribution to a different field due to their ability to look at a problem with a uni

Inside: A Recap of VitaDAO’s 2nd “Crypto meets Longevity Symposium” VitaDAO Fellowship Update New VitaSpotlight Series: Rapamycin as a Promising Aging Intervention How to contribute to VitaDAO and ResearchHub’s Community Driven Paper Meet DAO Membe

It was in 1975 when scientists from Ayerst (now Pfizer) discovered a novel compound called rapamycin (also known as Sirolimus) in bacteria on Rapa Nui(Easter Island) in Chile. In 1999 rapamycin obtained FDA approval for the prevention of acute reject

Some species in the animal kingdom live extraordinarily long lives. They seem to be somehow protected from all the damage that we would expect to accumulate in aged tissues. Many are very large, like bowhead whales, and there is an established correl

The transfer of technology (TT) is essential in turning intellectual property (IP) generated from innovative research into real-world applications that benefit the general public.

Welcome back to our monthly newsletter! This month we are excited to bring you an interview with Dr. Marco Demaria who has made some significant contributions to our understanding of cellular senescence. 

We can all agree that the age-associated decline in physiological functionality and increased risk of developing diseases is terrible, but what can we do to treat, slow down or even prevent it?

We are announcing The Longevity Prize in collaboration with Foresight.‍ A series of prizes to honor and accelerate progress in longevity and rejuvenation. ‍The longevity prize encourages novel approaches for turning back our aging clocks.

Why do we age? Is aging a result of a genetic program encoded within each of our cells, or is it simply a consequence of damage accumulation throughout life?

Welcome back to VitaDAO’s monthly longevity research newsletter — we hope you enjoyed our maiden issue!

Welcome Vitalians to the inaugural issue of VitaDAO’s Monthly Longevity Research Newsletter!

Humans can instinctively recognize if someone appears older or younger than their age; so then, it should be apparent that many species, including humans, develop age-related changes at different rates.

Originally described as gradual deterioration over time, senescence has taken on a much more intricate meaning in the past few decades.

We are getting quite good at extending lifespan, or at least we are getting quite good at extending the lifespan of laboratory animals as complex as mice.

We’re excited to introduce the opening project to be funded by VitaDAO — the world’s first decentralized intellectual property collective.